Newly-listed Techno Drugs reported a 24% year-on-year decline in profit, posting Tk 78 million for the first quarter through September of FY25. The drop in earnings was attributed to lower sales driven by reduced government demand, with sales revenue falling 30% to Tk 1.02 billion. The increase in the number of shares following the company’s IPO issuance also contributed to the reduced earnings per share (EPS), which dropped from Tk 1.09 in Q1 FY24 to Tk 0.63 in Q1 FY25. The company raised Tk 1 billion in June 2024 to purchase new machinery and reduce bank loans.
Despite the quarterly decline, Techno Drugs saw a 43% increase in annual profit for FY24, reaching Tk 280 million. The board declared a 12% cash dividend for general investors. The company is a major supplier of hormonal products to the Ministry of Family Planning and also exports medicines to countries like India, Germany, Nepal, and the Philippines.